Abstract
BackgroundIn recent years, immunotherapy has advanced the cancer field by achieving more durable patient response with a relatively tolerable toxicity. However, the overall response rates remain low (< 20%),1 mainly...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have